Omeprazol Tecnigen (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Tecnigen, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children.

GNH USA supplies Omeprazol Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders.

- Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSAID‑associated ulcer prophylaxis: lowers the risk of ulcer development in patients requiring long‑term NSAID therapy.

Adverse reactions to omeprazole are generally dose‑related and may vary in frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea or abdominal discomfort. - Flatulence or bloating. - Constipation. - Dry mouth.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema). - Clostridioides difficile‑associated colitis. - Low magnesium levels (hypomagnesemia) with prolonged use. - Vitamin B12 deficiency with long‑term therapy. - Bone fractures linked to chronic use. - Acute interstitial nephritis.

When prescribing omeprazole, clinicians should consider several safety aspects.

- Assess renal and hepatic function: dose adjustment may be required in severe impairment. - Review concomitant medications: potential for drug‑drug interactions. - Monitor long‑term users: watch for nutrient deficiencies and bone health. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Elderly patients: start at the lowest effective dose and monitor for adverse effects. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir and other protease inhibitors: decreased absorption, loss of antiviral efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation parameters. - Methotrexate: reduced renal clearance, watch for toxicity. - Digoxin: increased serum concentrations, assess cardiac status. - Phenytoin: altered metabolism, monitor seizure control. - Iron salts: decreased absorption, separate dosing times.